Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Efficacy of Ranibizumab Treatment Every 2 Month Compared to Treatment on Demand on Patients With Choroidal Neo-vascularization (CNV) as a Consequence of Age-related Macular Degeneration (AMD)

Authors not listed

Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH · 2010

Abstract

This clinical trial investigates the impact of intravitreal injection of Ranibizumab antibody on the acuteness of vision. Patients included are suffering from choroidal neo-vascularization (CNV) as a consequence of age-related macular degeneration (AMD). Initially, all patients get injections of 0.5 mg Ranibizumab in monthly intervals for 3 months. Subsequently, one group gets Ranibizumab in intervals of 2 months, whereas a second group is treated on demand. The primary end point of the study is the change of best-corrected visual acuity after 12 month. Secondary end points include the impact of Ranibizumab on morphological changes of the retina, the number of patients with gain or loss of 15 or more letters visual acuity after 12 months, changes in quality of life and the number of injections required during the first 12 months of treatment.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-15 MST

Cite this

APA
Anonymous. (2010). Efficacy of Ranibizumab Treatment Every 2 Month Compared to Treatment on Demand on Patients With Choroidal Neo-vascularization (CNV) as a Consequence of Age-related Macular Degeneration (AMD). <em>Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH</em>. https://clinicaltrials.gov/study/NCT01831947
Vancouver
Anonymous. Efficacy of Ranibizumab Treatment Every 2 Month Compared to Treatment on Demand on Patients With Choroidal Neo-vascularization (CNV) as a Consequence of Age-related Macular Degeneration (AMD). Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH. 2010.
BibTeX
@misc{anon2010Effica, title = {Efficacy of Ranibizumab Treatment Every 2 Month Compared to Treatment on Demand on Patients With Choroidal Neo-vascularization (CNV) as a Consequence of Age-related Macular Degeneration (AMD)}, author = {Anonymous}, journal = {Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH}, year = {2010}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings